CHI Logo

 

Overview
Table of Contents
Order 
Additional Reports 

Brochure Cover
Download Brochure 

Publication Date: 
January 2011

Page Count: 1,100

Price:
$2,995 Single User
$4,495 Multiple User
$8,985 Single Site
$14,975 Global License

Partnering Agreements in Pharma and Biotech Yearbook 2010 - Overview

 

Summary

The Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2010.

  • Bigpharma partnering activity during 2010
  • Top partnering deals by value in 2010
  • Top M&A deals by value in 2010
  • Most active dealmakers 2010
  • Comprehensive coverage of every deal announced in 2010

 

> Download Brochure 

Description

The Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 report provides comprehensive understanding and unprecedented access to the partnering and M&A deals and agreements entered into by the worlds leading healthcare companies during 2010.

Using this report, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report allows you to view all the partnering, alliances and M&A deals announced worldwide.

Chapter 1 provides an introduction to the report, whilst chapters 2 and 3 provide an overview of partnering and M&A trends, respectively, in 2010. The key partnering and M&A deals of 2010 are reviewed.

Chapter 4 analyzes the most active dealmakers in partnering and M&A during 2010.

Chapter 5 provides an overview of the leading deals for 2010 by headline value. The chapter provides covers both partnering and M&A dealmaking during the year.

The main body of the report is provided in chapters 6 and 7. Chapter 6 provides an in-depth review of every bigpharma company provides the reader with a breakdown of that company’s dealmaking during 2010 by deal type, stage of development and therapy focus. Each company entry is supplemented with a comprehensive listing of deals entered into during 2010, complete with a hyperlink to the deal record online. Where a contract document is available, this may also be found in the deal record online as filed with the SEC.

Chapter 7 provides a comprehensive directory of partnering and M&A activity during 2010. The deals are listed by deal type, stage of development and therapy focus, allowing easy access to deals and alliances of interest. Every deal record links to an online, live version of the deal record at the Current Agreements deals and alliances database. Where available, deal records also include the contract document as disclosed at the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of prospective partners’ negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the reader with the resources necessary to make research and understand the partnerships, alliances and M&A deals of 2010.

Key benefits

Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 provides the reader with the following key benefits:

  • In-depth understanding of recent dealmaking trends since 2005 to 2010
  • Comprehensive access to over 1,500 actual deals entered into by the world’s biopharma companies during 2010
  • Detailed access to actual partnership and M&A deals and contracts entered into by the leading fifty bigpharma companies
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 is intended to provide the reader with an in-depth understanding and access to parthering and M&A trends and structure of deals entered into by leading companies worldwide.

Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 includes:

  • Trends in dealmaking in the biopharma industry since 2005
  • Analysis of partnering and M&A deal structure
  • Comprehensive directory of partnering and M&A deals in 2010
  • Links to online access to over 1,500 partnering and M&A deals
  • The leading partnering and M&A deals by value in 2010
  • Most active partnering and M&A dealmakers during 2010

 

In Partnering and M&A Deals in Pharma and Biotech Yearbook 2010, the partnering and M&A deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Partnering and M&A Deals in Pharma and Biotech Yearbook 2010 report provides comprehensive links to online access to over 1,500 partnering and M&A deals. Where available, deals also include the contract document as disclosed at the SEC. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise companion diagnostics rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
By Series:
By Region: